MétaCan
Menu
Back to cohort
Record W4400111845 · doi:10.1002/cncr.35457

Roadmap for the next generation of Children’s Oncology Group rhabdomyosarcoma trials

2024· article· en· W4400111845 on OpenAlexaff
Jonathan Metts, Jamie M. Aye, Jacquelyn Crane, Sapna Oberoi, Frank M. Balis, Smita Bhatia, Kira Bona, Bruce Carleton, Roshni Dasgupta, Filemon S. Dela Cruz, Katie A. Greenzang, Jonathan L. Kaufman, Corinne M. Linardic, Susan K. Parsons, Mark Robertson‐Tessi, Erin R. Rudzinski, Alice Soragni, Elizabeth Stewart, Brenda J. Weigel, Suzanne L. Wolden, Aaron R. Weiss, Rajkumar Venkatramani, Christine M. Heske

Bibliographic record

VenueCancer · 2024
Typearticle
Languageen
FieldMedicine
TopicSarcoma Diagnosis and Treatment
Canadian institutionsUniversity of British ColumbiaUniversity of ManitobaCancerCare Manitoba
FundersNational Cancer InstituteNational Institutes of Health
KeywordsMedicineRhabdomyosarcomaOncologyPediatric oncologyInternal medicineClinical trialMedical physicsCancerPathologySarcoma

Abstract

fetched live from OpenAlex

Clinical trials conducted by the Intergroup Rhabdomyosarcoma (RMS) Study Group and the Children's Oncology Group have been pivotal to establishing current standards for diagnosis and therapy for RMS. Recent advancements in understanding the biology and clinical behavior of RMS have led to more nuanced approaches to diagnosis, risk stratification, and treatment. The complexities introduced by these advancements, coupled with the rarity of RMS, pose challenges to conducting large-scale phase 3 clinical trials to evaluate new treatment strategies for RMS. Given these challenges, systematic planning of future clinical trials in RMS is paramount to address pertinent questions regarding the therapeutic efficacy of drugs, biomarkers of response, treatment-related toxicity, and patient quality of life. Herein, the authors outline the proposed strategic approach of the Children's Oncology Group Soft Tissue Sarcoma Committee to the next generation of RMS clinical trials, focusing on five themes: improved novel agent identification and preclinical to clinical translation, more efficient trial development and implementation, expanded opportunities for knowledge generation during trials, therapeutic toxicity reduction and quality of life, and patient engagement.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.187
metaresearch head score (Gemma)0.111
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.187
Threshold uncertainty score0.990

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1870.111
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.005
Bibliometrics0.0020.001
Science and technology studies0.0020.003
Scholarly communication0.0120.007
Open science0.0050.009
Research integrity0.0100.012
Insufficient payload (model declined to judge)0.0170.005

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.216
GPT teacher head0.414
Teacher spread0.198 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueCancerSame topicSarcoma Diagnosis and TreatmentFrench-language works237,207